Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Does vitamin K prophylaxis prevent bleeding in neonates exposed to enzyme-inducing antiepileptic drugs in utero?

Literature DB >> 16812962

Does vitamin K prophylaxis prevent bleeding in neonates exposed to enzyme-inducing antiepileptic drugs in utero?

Massoud Rezvani¹, Gideon Koren.
1. Motherisk Program.

Abstract

QUESTION: One of my epileptic patients takes carbamazepine. She is 36 weeks pregnant and has asked me whether she should start vitamin K to prevent neonatal bleeding. Does current evidence support this practice? ANSWER: Recent evidence does not support the notion that newborns of women treated with enzyme-inducing anticonvulsant drugs are at increased risk of hemorrhagic disease. Antenatal vitamin K can be prescribed on an individualized basis in certain circumstances, such as imminent premature delivery.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2006 PMID： 16812962 PMCID： PMC1780148

Source DB: PubMed Journal: Can Fam Physician ISSN： 0008-350X Impact factor: 3.275

Keyword Cloud
References

15 in total

1. [New aspects of hemorrhagic disease of the newborn].

Authors: S VAN CREVELD
Journal: Arch Fr Pediatr Date: 1958

2. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:
Journal: Neurology Date: 1998-10 Impact factor: 9.910

10. Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation.

Authors: J A Thorp; D Ferrette-Smith; L A Gaston; J Johnson; J D Yeast; B Meyer
Journal: Obstet Gynecol Date: 1995-07 Impact factor: 7.661

Does vitamin K prophylaxis prevent bleeding in neonates exposed to enzyme-inducing antiepileptic drugs in utero?

1. [New aspects of hemorrhagic disease of the newborn].

2. Practice parameter: management issues for women with epilepsy (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Review 3. Hemorrhagic disease of the newborn after maternal anticonvulsant therapy: a case report and literature review.

4. Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy.

5. Splenic hemorrhage in a neonate of a mother on anticonvulsant therapy.

6. Maternal anticonvulsant therapy and hemorrhagic disease of the newborn.

7. Prothrombin and PIVKA-II levels in cord blood from newborn exposed to anticonvulsants during pregnancy.

8. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate.

9. Analysis of prenatal and gestational care given to women with epilepsy.

10. Combined antenatal vitamin K and phenobarbital therapy for preventing intracranial hemorrhage in newborns less than 34 weeks' gestation.